Provided by Tiger Trade Technology Pte. Ltd.

Legend Biotech

18.64
-0.5500-2.87%
Post-market: 18.850.2100+1.13%19:38 EDT
Volume:4.28M
Turnover:80.23M
Market Cap:3.63B
PE:-37.22
High:19.85
Open:19.48
Low:18.61
Close:19.19
52wk High:37.50
52wk Low:16.24
Shares:194.49M
Float Shares:91.34M
Volume Ratio:3.10
T/O Rate:4.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5008
EPS(LYR):-1.6200
ROE:-8.08%
ROA:-1.92%
PB:2.95
PE(LYR):-11.51

Loading ...

Legend Biotech Shares Down 3.7% Premarket; Ying Huang Steps Down as CEO and Board Member, Alan Bash Appointed Interim CEO

THOMSON REUTERS
·
Jul 27

Legend Biotech Names Alan Bash Interim CEO After Ying Huang Resigns

Reuters
·
Jul 27

Legend Biotech Corp - Ying Huang Steps Down as CEO and Board Member; to Remain as Advisor Through August

THOMSON REUTERS
·
Jul 27

Legend Biotech Corp - Alan Bash Appointed Interim CEO

THOMSON REUTERS
·
Jul 27

Legend Biotech Corp - Board Initiates Search for Permanent CEO Successor

THOMSON REUTERS
·
Jul 27

Legend Biotech Announces CEO Transition

THOMSON REUTERS
·
Jul 27

Legend Biotech Shares Fall After UBS Downgrade

MT Newswires Live
·
Jul 25

Legend Biotech Cut to Neutral from Buy by UBS

Dow Jones
·
Jul 24

UBS Downgrades Legend Biotech to Neutral From Buy, Adjusts Price Target to $28 From $49

MT Newswires Live
·
Jul 24

Legend Biotech downgraded to Neutral from Buy at UBS

TIPRANKS
·
Jul 24

Analysts Offer Insights on Healthcare Companies: Medicinova (MNOV), Legend Biotech (LEGN) and AngioDynamics (ANGO)

TIPRANKS
·
Jul 16

Genscript Highlights Strong CARVYKTI Sales via Legend Biotech, Urges Investor Caution

TIPRANKS
·
Jul 15

Legend Biotech: Carvykti® Generated About $657 Million in Net Trade Sales During Qtr Ended June 30, 2026

THOMSON REUTERS
·
Jul 15

Barclays Sticks to Its Buy Rating for Legend Biotech (LEGN)

TIPRANKS
·
Jul 14

Legend Biotech Price Target Announced at $35.00/share by JP Morgan

Dow Jones
·
Jul 13

Legend Biotech is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 08

RBC Capital Adjusts Legend Biotech Price Target to $63 From $64, Maintains Outperform Rating

MT Newswires Live
·
Jul 07

Legend Biotech Insider Move: Director Offloads Stake in High-Profile Transaction

TIPRANKS
·
Jul 03

Legend Biotech Director Casey Patrick John Disposes of 6,000 Common Shares for $88,800

Reuters
·
Jul 03

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.d., to Board of Directors

THOMSON REUTERS
·
Jun 23